Moderna’s experimental mRNA cancer treatment progresses, shares spike
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.
Moderna's experimental mRNA cancer treatment has shown promising results, leading to a significant increase in the company's share price. The treatment, known as intismeran, is tailored to individual patients based on unique mutations within their tumors. In initial studies, intismeran was paired with Merck's immunotherapy drug Keytruda.
Patients who received the combination of intismeran and Keytruda lived longer without cancer returning or metastasizing compared to those who received Keytruda alone. The companies have not disclosed the exact duration of survival without cancer returning or overall survival rates. They stated that they intend to present the study results at an upcoming international medical meeting.
Moderna's shares experienced a more than 120% increase, reaching $140.12 per share, while Merck's shares rose by approximately 11%.
Written by urgent.news from Global News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
